Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have become a pillar of advanced melanoma treatment. Given the moderate response rate to ICIs in metastatic melanoma patients and the potentially severe toxicity of ICIs, the distinction between nonresponders and responders is crucial and challengi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudura, Ken, Nussbaumer, Lukas, Foerster, Robert, Basler, Lucas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496082/
https://www.ncbi.nlm.nih.gov/pubmed/36140238
http://dx.doi.org/10.3390/biomedicines10092135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496082/
https://www.ncbi.nlm.nih.gov/pubmed/36140238
http://dx.doi.org/10.3390/biomedicines10092135

Ejemplares similares